Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo-Reference-Cited by-同舟云学术

Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo

Published:2021-07 Issue: Volume:219 Page:113428
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Liu Yi-Min^ORCID,Tu Huang-Ju^ORCID,Wu Chueh-Heng,Lai Mei-Jung^ORCID,Yu Shu-Chieh,Chao Min-Wu,Wu Yi-Wen,Teng Che-Ming,Pan Shiow-Lin^ORCID,Liou Jing-Ping

Funder

Ministry of Science and Technology, Taiwan

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference22 articles.

1. HSP90 and the chaperoning of cancer;Whitesell;Nat. Rev. Canc.,2005

2. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer;Gupta;Eur. J. Med. Chem.,2019

3. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review);Solárová;Int. J. Oncol.,2015

4. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: overview and current state of the art;Mellatyar;Biomed. Pharmacother.,2018

5. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships;Schnur;J. Med. Chem.,1995

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies;Journal of Hematology & Oncology;2024-09-04

2. Small molecule inhibitors targeting heat shock protein 90: An updated review;European Journal of Medicinal Chemistry;2024-09

3. HSP90: A promising target for NSCLC treatments;European Journal of Pharmacology;2024-03

4. Meta-Analysis of Diagnostic Value of Heat Shock Protein 90α in Lung Cancer Patients;Advances in Clinical Medicine;2024

5. Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges;Pharmaceutics;2023-06-10